trial

Trial of D-Cycloserine in Schizophrenia

NCTId NCT00000371
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 60 (actual)
Sponsored by Massachusetts General Hospital
Primary completion 2002-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
60 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
1996-08
Primary completion
2002-04
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
d-cycloserine

Sponsors

Massachusetts General HospitalLead Sponsor

Investigators

1
Donald C. Goff, MDPrincipal Investigator

Sites

0 total

Linked catalysts

1
Trial of D-Cycloserine in Schizophrenia — primary completion2002-04

Facts & assertions

4 sourced
Enrollment
60
Phase
PHASE3
Primary Completion Date
2002-04
Status
COMPLETED
relationships
The graph out of here
drug
d-cycloserine
drug
lead_sponsor
Massachusetts General Hospital
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Donald C. Goff, MD
person